20 Jun 2025 • A new study of 19,720 atopic dermatitis (AD) patients found that dupilumab was linked to a 58% higher risk of psoriasis (HR 1.58), with a number needed to harm of 94.

Key Findings:

• Over three years, psoriasis incidence was 2.86% with dupilumab vs 1.79% with other systemic agents.
• The risk remained across AD subgroups and was validated in asthma patients without AD (HR 2.13).

While the absolute risk remains low, these findings suggest that T helper 2 blockade by dupilumab may shift immune balance toward a T helper 17-dominant response, triggering psoriasis in susceptible individuals.

Source: JAMA Network | Read Full Story